Federal grants to Inhalon Biopharma, Inc.
Inhalon Biopharma, Inc. in Morrisville, North Carolina received $12.8 million in federal grants from fiscal 2021 to 2025, across 7 awards. Its largest program was Allergy and Infectious Diseases Research, with $12.8 million. In fiscal 2025 it was awarded $5.7 million.
From USAspending.gov award records, updated November 7, 2026.
- Grants, FY 2021 to 2025$12.8 million
- Awards7
- Awarded in FY 2025$5.7 million
- Largest award$2.6 million
By year
| Fiscal year | Awards | Amount |
|---|---|---|
| FY 2021 | 0 | $0 |
| FY 2022 | 1 | $1.0 million |
| FY 2023 | 2 | $2.0 million |
| FY 2024 | 4 | $4.1 million |
| FY 2025 | 6 | $5.7 million |
Programs that fund Inhalon Biopharma, Inc.
| Program | Awards | Amount |
|---|---|---|
| Allergy and Infectious Diseases Research | 7 | $12.8 million |
Awarding agencies
| Agency | Awards | Amount |
|---|---|---|
| Department of Health and Human Services | 7 | $12.8 million |
Largest awards
| Award | Program | First action | Amount |
|---|---|---|---|
| Gmp manufacturing and ind filing of IN-002, a potent inhaled muco-trapping antibody therapy for respiratory syncytial virus - title: gmp manufacturing and ind filing of IN-002, a potent inhaled “muco-trapping” antibody therapy for respiratory syncytial virus project summary (30 line limit) respirato | Allergy and Infectious Diseases Research | May 26, 2023 | $2.6 million |
| Pharmacokinetics analysis from first-in-human study of IN-002, a potent inhaled muco-trapping antibody therapy for rsv - project summary respiratory syncytial virus (RSV) is the leading cause of viral hospitalization and death in infants and young children, and also a major cause of respiratory illn | Allergy and Infectious Diseases Research | June 21, 2024 | $2.0 million |
| Ind-enabling development for IN-003, an inhaled mab therapy against human metapneumovirus infection - project summary human metapneumovirus (MPV) is the second leading cause of lower respiratory tract infections (LRTI) in infants and young children, and a major cause of respiratory illness among the | Allergy and Infectious Diseases Research | May 15, 2024 | $2.0 million |
| Sbir: ind-enabling development of IN-007, an inhaled muco-trapping immunotherapy for COVID19 and other ACE2-TARGETED infections - project summary despite the rollout of vaccines and paxlovid for SARS-COV-2, there continues to be significant demand for treatments for COVID-19 that (i) can be easily s | Allergy and Infectious Diseases Research | March 1, 2024 | $2.0 million |
| Ind-enabling development for IN-002, an inhaled muco-trapping mab against respiratory syncytial virus - project summary respiratory syncytial virus (RSV) is the leading cause of viral death in infants and young children, and is also a major cause of respiratory illness in immune compromised adults a | Allergy and Infectious Diseases Research | July 12, 2022 | $2.0 million |
| Development of IN-003PI as passive immunization against human metapneumovirus infection - project summary human metapneumovirus (MPV) is the second leading cause of lower respiratory tract infections (LRTI) in infants and young children, and a major cause of respiratory illness in the immunocompromi | Allergy and Infectious Diseases Research | September 2, 2025 | $1.0 million |
| Ind-enabling development for IN-005, an inhaled muco-trapping mab therapy against influenza a - project summary seasonal influenza virus (INFV) infections represent a major public health burden. Although flu vaccines are broadly available, they only offer modest effectiveness and have limited uptake | Allergy and Infectious Diseases Research | July 30, 2025 | $1.0 million |
Questions people ask
How much federal grant money does Inhalon Biopharma, Inc. get?
$12.8 million in 7 grant awards from fiscal 2021 to 2025, as obligations reported to USAspending.gov.
Which agency gives Inhalon Biopharma, Inc. the most?
The Department of Health and Human Services, with $12.8 million in 7 awards.
What is Inhalon Biopharma, Inc.'s largest federal grant?
$2.6 million under Allergy and Infectious Diseases Research, with its first action in the period on May 26, 2023. That counts only the money obligated in fiscal 2021 to 2025.
Other grant recipients in Morrisville
- Susteon Inc
- Ascent Bio-Nano Technologies, Inc.
- Civatech Oncology, Inc.
- Attagene Inc
- Soil Health Institute
- Vast Therapeutics, Inc.
- Alliance Health
- Nala Membranes Inc
Largest federal grant recipients in North Carolina · Federal grants in North Carolina